Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ekwegbara C"'
Autor:
Lucibello F; Department of Immunity and Cancer, Inserm U932, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France., Lalanne AI; Laboratoire d'Immunologie Clinique, Institut Curie , Paris, France.; Centre d'investigation Clinique en Biothérapie Gustave-Roussy Institut Curie (CIC-BT1428) , Paris, France., Le Gac AL; Department of Immunity and Cancer, Inserm U932, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France., Soumare A; Department of Immunity and Cancer, Inserm U932, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France., Aflaki S; Department of Immunity and Cancer, Inserm U932, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France., Cyrta J; Departments of Pathology, Institut Curie, Paris, France., Dubreuil L; Laboratoire d'Immunologie Clinique, Institut Curie , Paris, France., Mestdagh M; Department of Immunity and Cancer, Inserm U932, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France., Salou M; Department of Immunity and Cancer, Inserm U932, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France., Houy A; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, PSL University, Institut Curie , Paris, France., Ekwegbara C; Laboratoire d'Immunologie Clinique, Institut Curie , Paris, France.; Centre d'investigation Clinique en Biothérapie Gustave-Roussy Institut Curie (CIC-BT1428) , Paris, France., Jamet C; Department of Immunity and Cancer, Inserm U932, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France., Gardrat S; Departments of Pathology, Institut Curie, Paris, France., Le Ven A; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, PSL University, Institut Curie , Paris, France., Bernardeau K; Centre Hospitalier Universitaire (CHU) Nantes, Centre National de la Recherche Scientifique, Inserm, BioCore, US16, Nantes Université , Nantes, France., Cassoux N; Department of Surgical Oncology, University of Paris, Institut Curie, Paris, France., Matet A; Department of Surgical Oncology, University of Paris, Institut Curie, Paris, France., Malaise D; Department of Surgical Oncology, University of Paris, Institut Curie, Paris, France., Pierron G; Department of Genetics, Institut Curie, Paris, France., Piperno-Neumann S; Department of Medical Oncology, Institut Curie, Paris, France., Stern MH; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, PSL University, Institut Curie , Paris, France., Rodrigues M; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, PSL University, Institut Curie , Paris, France.; Department of Medical Oncology, Institut Curie, Paris, France., Lantz O; Department of Immunity and Cancer, Inserm U932, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France.; Laboratoire d'Immunologie Clinique, Institut Curie , Paris, France.; Centre d'investigation Clinique en Biothérapie Gustave-Roussy Institut Curie (CIC-BT1428) , Paris, France.
Publikováno v:
The Journal of experimental medicine [J Exp Med] 2024 Jun 03; Vol. 221 (6). Date of Electronic Publication: 2024 Apr 02.
Autor:
Borcoman E; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Translational Immunotherapy Team, Translational Research Department, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France., Lalanne A; INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France; CIC IGR-Curie 1428, Center of Clinical Investigation, Institut Curie, Paris, France., Delord JP; Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France., Cassier PA; Department of Medical Oncology-Centre Leon Bérard, Lyon, France., Rolland F; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint Herblain, France., Salas S; CEPCM Hôpital Timone, Marseille, France; Aix Marseille University, Marseille, France., Limacher JM; Department of Medical Oncology, Hôpitaux Civils de Colmar, Colmar, France., Capitain O; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Site Paul Papin, Angers, France., Lantz O; INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France; CIC IGR-Curie 1428, Center of Clinical Investigation, Institut Curie, Paris, France., Ekwegbara C; INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France; CIC IGR-Curie 1428, Center of Clinical Investigation, Institut Curie, Paris, France., Jeannot E; Department of Pathology and Genetics, Institut Curie, Paris, France., Cyrta J; Department of Pathology and Genetics, Institut Curie, Paris, France., Tran-Perennou C; Department of Pathology and Genetics, Institut Curie, Paris, France., Castel-Ajgal Z; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Marret G; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Piaggio E; INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Translational Immunotherapy Team, Translational Research Department, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France., Brandely M; Transgene S.A., Illkirch-Graffenstaden, France., Tavernaro A; Transgene S.A., Illkirch-Graffenstaden, France., Makhloufi H; Transgene S.A., Illkirch-Graffenstaden, France., Bendjama K; Transgene S.A., Illkirch-Graffenstaden, France., Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; INSERM U900, Institut Curie, Mines Paris Tech, Saint-Cloud, France; Paris-Saclay University, Paris, France. Electronic address: christophe.letourneau@curie.fr.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Sep; Vol. 191, pp. 112981. Date of Electronic Publication: 2023 Jul 11.
Autor:
Le Tourneau, C., Cassier, P., Rolland, F., Salas, S., Limacher, J-M., Capitain, O., Lantz, O., Lalanne, A., Ekwegbara, C., Tavernaro, A., Makhloufi, H., Bendjama, K., Delord, J-P.
Publikováno v:
In Annals of Oncology December 2020 31 Supplement 7:S1442-S1442
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Borcoman, Edith1 (AUTHOR) edith.borcoman@curie.fr, Marret, Gregoire1 (AUTHOR) gregoire.marret@curie.fr, Le Tourneau, Christophe1,2,3 (AUTHOR) Christophe.LeTourneau@curie.fr
Publikováno v:
Cancers. Jun2021, Vol. 13 Issue 11, p2573. 1p.